NCT07213518View on ClinicalTrials.gov

High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients

NACompletedINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

July 1, 2022

Study Completion Date

January 1, 2023

Conditions

COVID-19 Pneumonia

Interventions

DEVICE

High Velocity Nasal Insufflation

COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received High Velocity Nasal Insufflation

DEVICE

Continuous Positive Airway Pressure

COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received Continuous Positive Airway Pressure

Trial Locations (1)

35516

Mohamed AbdElmoniem, Al Mansurah

All Listed Sponsors

lead

Mansoura University

OTHER

NCT07213518 - High Velocity Nasal Insufflation Versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients | Biotech Hunter | Biotech Hunter